Skip to content
Inciteful Med

Supportive Care and Surgical Options

Last updated:

Managing CMT1A requires a multidisciplinary approach focused on maximizing mobility and preventing complications. Key treatments include physical therapy, AFO bracing for foot drop, surgical correction for foot deformities, and strict avoidance of neurotoxic medications and high blood sugar.

Key Takeaways

  • • Multidisciplinary care from neurologists, physical therapists, and orthopedists is essential for managing CMT1A symptoms.
  • • Ankle-Foot Orthoses (AFOs), particularly carbon AFOs, help compensate for foot drop and significantly reduce the risk of falls.
  • • Surgical interventions like osteotomies and tendon transfers can correct painful cavovarus foot deformities to create a flat, stable foot.
  • • Patients must strictly avoid neurotoxic medications, as they can cause irreversible damage to already compromised peripheral nerves.
  • • Controlling blood sugar is critical, because diabetes significantly accelerates nerve fiber loss in people with CMT1A.

Managing Charcot-Marie-Tooth disease type 1A (CMT1A) currently requires a multidisciplinary approach. Because there is no cure that addresses the underlying genetic duplication, the “standard of care” focuses on maximizing mobility, managing symptoms like pain and fatigue, and preventing secondary complications [1][2].

The Multidisciplinary Team

A comprehensive care plan often involves a team of specialists working together. Because finding doctors who truly understand CMT1A can be exhausting, organizations like the CMT Association (CMTA) and the Hereditary Neuropathy Foundation (HNF) offer directories of Centers of Excellence. These centers provide coordinated care from experts in the field.

  • Neurologists: To monitor disease progression using tools like the CMT Neuropathy Score (CMTNS) [3][4].
  • Physical and Occupational Therapists (PT/OT): To design tailored exercise programs that focus on balance, “power-based” resistance, and daily living skills [5][6].
  • Orthotists: To fit and maintain bracing, which is essential for stabilizing the gait [1].
  • Orthopedic Surgeons: To address structural foot and ankle changes that no longer respond to bracing [7].

Orthotics and Physical Therapy

Bracing is a cornerstone of CMT1A management. Ankle-Foot Orthoses (AFOs) help compensate for “foot drop” and muscle weakness, significantly reducing the risk of falls [1][8].

  • Advanced Materials: Research shows that Carbon AFOs often provide better “push-off” power and are more satisfying for patients than traditional plastic (thermoplastic) braces [9].
  • Targeted Exercise: Low-impact, progressive resistance training is generally well-tolerated and can improve functional performance without damaging the nerves [5][10].

Surgical Interventions for Foot Deformities

When the characteristic cavovarus (high-arched, inward-turning) foot deformity becomes severe or painful, surgery may be necessary [7][11]. The goal is to create a “plantigrade” foot—one that sits flat on the ground [7].

  1. Soft-Tissue Release: For “flexible” deformities, surgeons may lengthen tight tendons or move them (tendon transfer) to balance the foot’s pull [12][7].
  2. Osteotomies: This involves cutting and repositioning bones (like the heel bone or the bones of the midfoot) to correct the arch and alignment [7][13].
  3. Arthrodesis (Joint Fusion): For “fixed” or rigid deformities where joints have become arthritic, surgeons may fuse the bones together to provide a stable, painless base [12][14].

The Critical Role of Metabolic Health and Medication Safety

One of the most important aspects of managing CMT1A is protecting the nerve function you have left by avoiding external “accelerators” of nerve damage.

  • Avoiding Neurotoxic Medications: Certain common medications—including specific antibiotics, chemotherapy drugs, and even high doses of Vitamin B6—can be toxic to peripheral nerves and cause irreversible damage. It is crucial to review all new prescriptions against the CMTA’s Neurotoxic Medication Alert List and discuss them with your pharmacist or neurologist.
  • The Diabetes Connection: Having Type 2 Diabetes (T2DM) or even general glucose intolerance significantly worsens CMT1A [15][16].
  • Severe Nerve Loss: Research indicates that CMT1A patients with diabetes have much higher rates of nerve fiber loss and a reduced ability for their nerves to repair themselves compared to those without diabetes [16]. Maintaining strict blood sugar control and a healthy BMI is a vital part of protecting your long-term mobility [15][17].

Managing Pain and Fatigue

Pain is reported by over 80% of CMT1A patients and can be either structural (from the way you walk) or neuropathic (from the nerves themselves) [18][1]. While standard pain medications and physical therapies are often used, researchers are actively exploring new treatments to improve overall physical function, although the path to new drugs can be challenging [19].

Frequently Asked Questions

When should I consider custom AFO braces for CMT1A?
Custom Ankle-Foot Orthoses (AFOs) are typically recommended when you experience frequent tripping, foot drop, or significant muscle weakness. Advanced materials like carbon AFOs can be especially helpful for providing better push-off power and improving your overall gait stability.
What surgeries are used to treat CMT1A foot deformities?
Surgical options depend on the severity of your cavovarus foot deformity. Procedures can include soft-tissue releases for flexible feet, bone cuts called osteotomies to realign the arch, or joint fusions for rigid, arthritic joints to provide a stable walking base.
Why is blood sugar control important for people with CMT1A?
Having Type 2 diabetes or general glucose intolerance can significantly worsen nerve damage in CMT1A. Maintaining strict blood sugar control helps protect your remaining nerve function and prevents accelerated nerve fiber loss.
What are neurotoxic medications, and why should CMT1A patients avoid them?
Neurotoxic medications are drugs that can damage peripheral nerves, including certain antibiotics, chemotherapy drugs, and high doses of Vitamin B6. People with CMT1A should cross-check all new prescriptions with a neurotoxic medication list to prevent irreversible nerve damage.
What type of physical therapy is best for CMT1A?
Physical therapy for CMT1A should focus on low-impact, progressive resistance training, balance improvement, and daily living skills. A therapist specialized in neuromuscular diseases can design a safe program that improves functional performance without overworking damaged nerves.

Questions for Your Doctor

  • • Given my current foot structure, is it time to transition from off-the-shelf inserts to custom Ankle-Foot Orthoses (AFOs)?
  • • Can you refer me to a physical therapist who specializes in neuromuscular diseases to design a safe, low-impact resistance program?
  • • At what point should we consider surgical intervention for my or my child's foot deformity—is it better to do it while the foot is still 'flexible'?
  • • What specific surgical procedures (like osteotomy or tendon transfer) would be most appropriate for my or my child's foot alignment?
  • • How frequently should we be monitoring my blood sugar (HbA1c) to ensure it isn't contributing to my nerve damage?
  • • Are there any specific medications, like certain antibiotics or chemotherapy drugs, that I must strictly avoid because they are neurotoxic?

Questions for You

  • • How many times have I tripped or fallen in the last month, and what was I doing when it happened?
  • • Does my current footwear feel stable, or do I feel like I'm constantly 'rolling' my ankles?
  • • Am I avoiding certain activities because of foot or leg pain?
  • • On a scale of 1 to 10, how much does daily fatigue impact my ability to work, go to school, or enjoy hobbies?
  • • How consistently am I monitoring my metabolic health (weight and blood sugar), knowing its impact on CMT1A?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study.

    Thomas FP, Saporta MA, Attarian S, et al.

    Journal of clinical neuromuscular disease 2022; (24(1)):7-17 doi:10.1097/CND.0000000000000426.

    PMID: 36005469
  2. 2

    [Ascorbic Acid and Charcot-Marie-Tooth Disease].

    Noto Y

    Brain and nerve = Shinkei kenkyu no shinpo 2015; (67(10)):1241-6 doi:10.11477/mf.1416200289.

    PMID: 26450076
  3. 3

    Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.

    Mandarakas MR, Eichinger KJ, Bray P, et al.

    Neurology 2024; (102(3)):e207963 doi:10.1212/WNL.0000000000207963.

    PMID: 38237108
  4. 4

    Intraepineurial fat quantification and cross-sectional area analysis of the sciatic nerve using MRI in Charcot-Marie-Tooth disease type 1A patients.

    Kim HS, Lee JH, Yoon YC, et al.

    Scientific reports 2021; (11(1)):21535 doi:10.1038/s41598-021-00819-0.

    PMID: 34728674
  5. 5

    Collaborative Therapist-Patient Decision Making: A Power-Based Exercise Program for an Adolescent With CMT1A.

    Hedgecock JB, Kelley C, Jensen A, Rapport MJ

    Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association 2023; (35(1)):101-107 doi:10.1097/PEP.0000000000000972.

    PMID: 36638038
  6. 6

    Handwriting difficulties of children with Charcot-Marie-Tooth disease type 1A.

    Kunovsky D, Cordier R, Bray P, Burns J

    Journal of the peripheral nervous system : JPNS 2017; (22(1)):34-38 doi:10.1111/jns.12198.

    PMID: 27917570
  7. 7

    Neurologic Disorders and Cavovarus Deformity.

    Neumann JA, Nickisch F

    Foot and ankle clinics 2019; (24(2)):195-203 doi:10.1016/j.fcl.2019.02.003.

    PMID: 31036264
  8. 8

    The impact of orthoses on gait in children with Charcot-Marie-Tooth disease.

    Õunpuu S, Garibay E, Acsadi G, et al.

    Gait & posture 2021; (85()):198-204 doi:10.1016/j.gaitpost.2021.02.005.

    PMID: 33610823
  9. 9

    Effect of Ankle-Foot Orthoses in Pediatric Patients with Hereditary Motor-Sensory Neuropathy: A Case Series Study.

    Borghi C, Sassi S, Pandarese D, et al.

    Children (Basel, Switzerland) 2023; (10(9)) doi:10.3390/children10091529.

    PMID: 37761490
  10. 10

    Orthopaedic shoes along with physical therapy was effective in Charcot-Marie-Tooth patient over 10 years.

    Bensoussan L, Jouvion A, Kerzoncuf M, et al.

    Prosthetics and orthotics international 2016; (40(5)):636-42 doi:10.1177/0309364615584657.

    PMID: 26015326
  11. 11

    Pes cavovarus in Charcot-Marie-Tooth compared to the idiopathic cavovarus foot: A preliminary weightbearing CT analysis.

    Bernasconi A, Cooper L, Lyle S, et al.

    Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons 2021; (27(2)):186-195 doi:10.1016/j.fas.2020.04.004.

    PMID: 32507338
  12. 12

    The adult cavus foot.

    Maynou C, Szymanski C, Thiounn A

    EFORT open reviews 2017; (2(5)):221-229 doi:10.1302/2058-5241.2.160077.

    PMID: 28630759
  13. 13

    Functional results and quality of life after joint preserving or sacrificing surgery in Charcot-Marie-Tooth foot deformities.

    Tejero S, Chans-Veres J, Carranza-Bencano A, et al.

    International orthopaedics 2021; (45(10)):2569-2578 doi:10.1007/s00264-021-04978-7.

    PMID: 33611670
  14. 14

    Charcot Foot.

    Zwipp H, Rammelt S, Dahlen C, Reichmann H

    Der Orthopade 1999; (28(6)):550-558 doi:10.1007/PL00003640.

    PMID: 28247006
  15. 15

    High glucose level as a modifier factor in CMT1A patients.

    Secchin JB, Leal RCC, Lourenço CM, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(2)):132-137 doi:10.1111/jns.12379.

    PMID: 32347995
  16. 16

    Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.

    Chao HC, Chou CT, Lee YC, Lin KP

    Journal of the neurological sciences 2015; (358(1-2)):213-20.

    PMID: 26349404
  17. 17

    Effectiveness of Sitagliptin and Empagliflozin Combination Therapy in a Patient With Charcot-Marie-Tooth Disease and Comorbid Diabetes Mellitus: A Case Report.

    Wada M, Mizuno Y, Kajiyama A, et al.

    Cureus 2025; (17(8)):e89954 doi:10.7759/cureus.89954.

    PMID: 40951209
  18. 18

    Prevalence and characterization of pain in patients with Charcot-Marie-Tooth disease type 1A.

    Azevedo H, Costa H, Davidovich E, et al.

    Arquivos de neuro-psiquiatria 2021; (79(5)):415-419 doi:10.1590/0004-282X-ANP-2020-0132.

    PMID: 34037101
  19. 19

    A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.

    Attarian S, Young P, Brannagan TH, et al.

    Orphanet journal of rare diseases 2021; (16(1)):433 doi:10.1186/s13023-021-02040-8.

    PMID: 34656144

This page provides educational information on supportive care and surgical options for CMT1A. Always consult your neurologist, physical therapist, or orthopedic specialist before changing your care plan or starting new physical activities.

Stay up to date

Get notified when new research about Charcot-Marie-Tooth disease type 1A is published.

No spam. Unsubscribe anytime.